 Image by Ousa Chea on Unsplash The clinical-stage biotech company Axcella NASDAQ: AXLA uses endogenous metabolic modulators EMMs to treat complex diseases, including liver conditions. One of its leading drug candidates, AXA1665, relies on a pioneering composition of amino acids to offer more comprehensive relief to patients suffering from progressively worsening effects resulting from cirrhosis. 